Approval · Notice of Compliance 937 · 2000
FOSAMAX: Notice of Compliance 937
Issued December 5, 2000
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 937
- Date
- December 5, 2000
- Company
- Merck Frosst Canada & Cie, Merck Frosst Canada & Co.Kirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Product monograph revision
- Therapeutic class
- Bone metabolism regulator
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| FOSAMAX | Not yet assigned | — |
Medicinal ingredients
- ALENDRONATE SODIUM 5 MG per TAB
- ALENDRONATE SODIUM 10 MG per TAB
- ALENDRONATE SODIUM 40 MG per TAB